Botox competitor is allowed back on US market
Xeomin is a form of botulinum toxin, injected in to problem areas of the face in order to eliminate wrinkles. It’s a direct competitor of Botox which is made and distributed by pharmaceutical company Allergan.
The Botox rival’s introduction on to the US market was halted when it transpired that staff had been recruited from Allergan to Merz, the company responsible for Xeomin. As a result it was believed that Allergan’s confidential knowledge and research was shared with the rival pharmaceutical.
However a new ruling means that its use is now approved for retail in the US allowing patients more choice over which injectible product to use. Xeomin has been available as an anti-wrinkle treatment in the UK since 2008. It currently accounts for around 20% of all anti-wrinkle injections.
Aurora Skin Clinics are an expert group of skin specialists offering Botox anti-wrinkle injections, as well as a range of other non-surgical treatments to improve the skin. For information on any of our treatments, contact us on 01844 211777 or email email@example.com.